All News
Mitigating Immunogenicity When Using Uricase Therapies as ULT
ACR20 convergence highlights a shift in gout management and uric acid lowering therapy (ULT). The new biologics pegdriticase and pegloticase are associated with risk of immunogenicity and loss of biological effects.
Read Article
Olga Petryna DrPetryna ( View Tweet)
Olga Petryna DrPetryna ( View Tweet)
How often do you order LDH, AST and triglycerides in AOSD cases?
Olga Petryna DrPetryna ( View Tweet)
@RheumNow #ACR20 abs1151 screening for inflammatory hyperferritinemia may be feasible but requires additional info: inflammatory huperferritinemia more likely to correlate with ⬆️IL18, AST&thrombocytosis while high CRP+ferritin more often seen in infectious etiology https://t.co/wiFPXepxpz
How many new Adult Onset Still's Disease patients have you seen in the past year? @RheumNow #ACR20
Bella Mehta bella_mehta ( View Tweet)
European Rheum Consortium (SHARE) recommendations for Rx of systemic JIA: 1) Systemic JIA - AOSD; 2) STEROIDs, 3) IL-1 inhibitors; 4) TCZ, 5) MTX & TNFi mainly for arthritis. Should be aware of risk for MAS and ILD #ACR20 Abstr#1148 https://t.co/mgZvLKNljs
Dr. John Cush RheumNow ( View Tweet)
Bella Mehta bella_mehta ( View Tweet)
@RheumNow #acr20 abs0098 CCL2&CCR2 may play role in inflammatory response in AOSD, high levels in active AOSD subside with six resolution. Correlate with CRP, neutrophil count& ferritin levels. Does not correlate w/ Clincial markers of disease activity
Olga Petryna DrPetryna ( View Tweet)
Interim analysis of the RELIANCE registry studying effect of canakinumab (CAN) in 80 patients w/ febrile CAPS. Efficacy of CAN assessed w/ AIDA (inflam index) showing ~70% were in low activity (<9) @ACR20 Abstr#1479 https://t.co/UC2eJbpVLM https://t.co/M71s8gXZY9
Links:
Peter Nash drpnash ( View Tweet)


